Cardiovascular research, clinical, basic, and transitional, is to a significant degree connected with industry. Industrial laboratories carry out extremely productive research, but also, in a variety of ways, industry reinforces and supports a large number of academic institutions so that they may respond to its needs.
It is, therefore, both reasonable and necessary to include as a main section of this site some of the developments in industry that overlap with our field.
It is easy to see that it would be overoptimistic to attempt to cover more than a small portion of the extremely important developments—scientific, organisational, and commercial—that occur every day in industrial research with a cardiovascular connection.
We do aspire, however, to provide visitors to the site with prompt and accurate information, albeit selective, concerning matters of primary importance.
This main section is divided into subunits that deal with topics useful and essential for those who, like our Society, are active in those areas.
Biotechnology. This branch of technology has extremely wide applications in cardiovascular medicine. Its development in recent years has been very rapid, especially in applications related to fields such as pharmacogenomics, drug production, etc. (For a useful summary see here.) Visitors to this subsection will have the opportunity to link to a number of selected topics (the biotechnology web galaxy) that although dissimilar, can contribute in a variety of ways to the advance of information.
Medical technology. It is easy to see why medical technology, the scientific field that combines science and technology in the the diagnosis and treatment of cardiovascular diseases, ranks highly in the priorities of our Society. We judge that it would beneficial to our members, and more generally to any visitors to the site who are interested in cardiovascular research, to offer a range of links to information concerning the activities of medical technology companies (the medical technology web galaxy).
- Williams B, Cockcroft JR, Kario K et al. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study
Hypertension. 2017;69:411-420. … more
- Aro AL, Rusinaru C, Uy-Evanado A et al. Syncope and risk of sudden cardiac arrest in coronary artery disease. Int. J. Cardiol. 2017; 231:26-30 … more
- Raaijmakers A, Zhang ZY, Claessens J et al. Does Extremely Low Birth Weight Predispose to Low-Renin Hypertension? Hypertension. 2017; 69:443-449. … more
- McCord J, Cabrera R, Lindahl B et al for the TRAPID-AMI Investigators. Prognostic Utility of a Modified HEART Score in Chest Pain Patients in the Emergency Department.
Circ Cardiovasc Qual Outcomes. 2017;10:e003101. … more
- Aisu H, Saito M, Inaba S et al. Association of worsening arterial stiffness with incident heart failure in asymptomatic patients with cardiovascular risk factors. Hypertens Res 2017 40: 173-180 … more
- Galløe AM, Kelbæk H, Thuesen L et al. 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. JACC 2017;69:616-624 … more
- Nielles-Vallespin, S., Khalique, Z., et al. Assessment of Myocardial Microstructural Dynamics by In Vivo Diffusion Tensor Cardiac Magnetic Resonance JACC 2017;69:661-676 … more
- Yeh, R. W., Silber, S., et al. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program . JACC:Cardiov. Interv. 2017;10:247-254 … more
- Rezkalla, S. H., Stankowski, R. V., et al. Management of No-Reflow Phenomenon in the Catheterization Laboratory. JACC:Cardiov. Interv. 2017;10:215-223 … more
- Mahabadi, A. A., Möhlenkamp, S., et al. CAC Score Improves Coronary and CV Risk Assessment Above Statin Indication by ESC and AHA/ACC Primary Prevention Guidelines.
JACC: Cardiov. Imag. 2017;10:143-153 … more